Body Weight, Aspirin Dose and Pro-resolving Mediators
DISCOVER: A Single-site Double-blind Placebo-controlled Randomized Mechanistic Crossover Trial to Assess the Influence of boDy weIght on aSpirin-triggered speCialized prO-resolVing mEdiatoRs
Sponsor: NYU Langone Health
A PHASE4 clinical study on Body Weight, this trial is completed. The trial is conducted by NYU Langone Health and has accumulated 15 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE4
-
Jun 2025 — Mar 2026 [monthly]
Completed PHASE4
-
May 2025 — Jun 2025 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2025 — May 2025 [monthly]
Active Not Recruiting PHASE4
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
▶ Show 10 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE4
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE4
-
Feb 2023 — Dec 2023 [monthly]
Recruiting PHASE4
-
Apr 2022 — Feb 2023 [monthly]
Recruiting PHASE4
-
Nov 2021 — Apr 2022 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE4
-
Feb 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NYU Langone Health
For direct contact, visit the study record on ClinicalTrials.gov .